Addex Therapeutics (ADXN) announced that it will present positive results from its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program at the Thirteenth London International Cough Symposium on July 19.
In guinea pig models of chronic cough, the candidate GABAB positive allosteric modulator (PAM) significantly and dose-dependently reduced cough frequency induced by citric acid (minimal efficacious dose 1 mg/kg), increased cough latency, and demonstrated no signs of tolerance following sub-chronic treatment.
Compared to the GABAB agonist baclofen, the selective GABAB PAM exhibited a wider safety margin by maintaining a separation between its minimal efficacious dose and the dose associated with side effects. Baclofen has antitussive properties but is limited in clinical use due to its short half-life and central nervous system side effects, such as sedation.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.